Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5705720 | 0.75 | EGFR (0.33) | EGFR | |
| SCHEMBL10441379 | 0.75 | EGFR (0.33) | EGFR | |
| SCHEMBL21676523 | 0.75 | ADORA1 (0.34) | EGFR | |
| SCHEMBL19421513 | 0.71 | ADORA2A (0.39) | EGFRPIK3CG | |
| SCHEMBL31260572 | 0.71 | EGFR (0.31) | EGFR | |
| SCHEMBL21178956 | 0.71 | EGFR (0.31) | EGFR | |
| SCHEMBL31507016 | 0.71 | EGFR (0.31) | EGFR | |
| SCHEMBL5786449 | 0.70 | ESR2 (0.43) | PIK3CG | |
| SCHEMBL140301 | 0.69 | EGFR (0.46) | EGFRPIK3CG | |
| SCHEMBL29809882 | 0.69 | EGFR (0.46) | EGFRPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8344118-B2 | Preparation and isolation of 5′ capped MRNA | APPLIED BIOSYSTEMS, LLC (US) | 2013-01-01 | — | — | US | disclosed |
| US-20120156751-A1 | PREPARATION AND ISOLATION OF 5' CAPPED MRNA | APPLIED BIOSYSTEMS, LLC (US) | 2012-06-21 | — | — | US | disclosed |
| US-8093367-B2 | Preparation and isolation of 5′ capped mRNA | APPLIED BIOSYSTEMS, LLC (US) | 2012-01-10 | — | — | US | disclosed |
| US-20100304389-A1 | Preparation And Isolation of 5' Capped mRNA | Life Technologies Corporation (US) | 2010-12-02 | — | — | US | disclosed |
| WO-2009058911-A2 | PREPARATION AND ISOLATION OF 5' CAPPED MRNA | APPLIED BIOSYSTEMS INC. (US) | 2009-05-07 | — | — | WO | disclosed |
| US-20040048866-A1 | Indazole derivatives that are activators of soluble guanylate cyclase | ABBOTT LABORATORIES | 2004-03-11 | — | — | US | disclosed |
| WO-2003076408-A2 | INDAZOLE DERIVATIVES THAT ARE ACTIVATORS OF SOLUBLE GUANYLATE CYCLASE | ABBOTT LABORATORIES (US) | 2003-09-18 | — | — | WO | disclosed |
| EP-0661979-A4 | CROSS-LINKING OLIGONUCLEOTIDES FOR ENZYME-MEDIATED TRIPLE STRAND FORMATION. | MICROPROBE CORP (US) | 1995-09-13 | — | — | EP | disclosed |
| EP-0661979-A1 | CROSS-LINKING OLIGONUCLEOTIDES FOR ENZYME-MEDIATED TRIPLE STRAND FORMATION | MICROPROBE CORPORATION (US) | 1995-07-12 | — | — | EP | disclosed |
| WO-1993003736-A1 | CROSS-LINKING OLIGONUCLEOTIDES FOR ENZYME-MEDIATED TRIPLE STRAND FORMATION | MICROPROBE CORPORATION (US) | 1993-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100304389-A1 | Preparation And Isolation of 5' Capped mRNA | RNGTT, RNMT, NSUN2 | EGFR 4562/4885PIK3CG 3357/4885 |
| US-20120156751-A1 | PREPARATION AND ISOLATION OF 5' CAPPED MRNA | RNGTT, RNMT, NSUN2 | EGFR 4562/4885PIK3CG 3357/4885 |
| US-20040048866-A1 | Indazole derivatives that are activators of soluble guanylate cyclase | GUCY1B1, GUCY1A1, GUCY1A2 | EGFR 4684/4885PIK3CG 3510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.